Publications by authors named "Darryn Bampton"

Claim this Profile
P
Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
Charlotte Lemech, Keith Dredge, Darryn Bampton, Edward Hammond, Andrew Clouston

J Immunother Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.
Edward Hammond, Nicole M Haynes, Carleen Cullinane, Todd V Brennan, Darryn Bampton

J Immunother Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.
Keith Dredge, Todd V Brennan, Edward Hammond, Jason D Lickliter, Liwen Lin, Darryn Bampton

Br J Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
Boris Winterhoff, Luisa Freyer, Edward Hammond, Shailendra Giri, Susmita Mondal, Darryn Bampton

Eur J Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis